%0 Journal Article
%T Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
%A Anne Overgaard
%A Henning Hansen
%A Maria Lajer
%A Lykke Pedersen
%A Lise Tarnow
%A Peter Rossing
%A James N McGuire
%A Flemming Pociot
%J Proteome Science
%D 2010
%I BioMed Central
%R 10.1186/1477-5956-8-4
%X Proteomic analysis of plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric, gave rise to 290 peaks clusters of which 16 were selected as the most promising biomarker candidates based on statistical performance, including independent component analysis. Four of the peaks that were discovered have been identified as transthyretin, apolipoprotein A1, apolipoprotein C1 and cystatin C. Several yet unidentified proteins discovered by this novel approach appear to have more potential as biomarkers for diabetic nephropathy.These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic patients.Diabetic nephropathy will affect approximately 30% of all patients with diabetes [1,2]. The proportion of patients that progress to end stage renal disease (ESRD) because of diabetic nephropathy has been estimated to be 7% [3] and as a consequence diabetic nephropathy is the most common cause of renal failure in the developed world [4,5]. Diabetic nephropathy advances through a number of recognizable steps from sub-clinical disease to the first measurable stage of microalbuminuria (MIC), defined as persistent albumin excretion levels in urine normalized to creatinine levels (U-albumin) of 30-300 mg/24 h, to macroalbuminuria/diabetic nephropathy (DMN) with U-albumin>300 mg/24 h. DMN is followed by renal dysfunction and ultimately ESRD. Although positive effects on the development and progression of diabetic nephropathy through strict control of blood glucose [6], blood pressure [7] and in particular blockade of the renin-angiotensin system [8,9] have been reported, it still has not been enough to prevent the high incidence of end stage kidney damage caused by diabetes. Administration of cardiovascular drugs, which are commonly prescribed for patient
%U http://www.proteomesci.com/content/8/1/4